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Pulsed Low Intensity Non-Focused Ultrasound (LINFU) was used to trigger the release from liposomes of
the clinically approved Magnetic Resonance Imaging (MRI) agent Gadoteridol. The extent of the release was
monitored by relaxometric measurements upon changing both ultrasound stimulus (power, application times
and mode, duty cycle values) and physico-chemical variables of the theranostic agent (liposomes size, shape,
chemical composition, and concentration of the encapsulated agent). The release was not heat-mediated, but
promoted by mechanical interactions between the acoustic radiation waves and the soft nanovesicles. The
application of pulsed LINFU led to a controlled release detectable by both Nuclear Magnetic Resonance (NMR)
relaxometry and MRI. Such promising observations were followed by an in vivo proof-of-concept study on a
syngeneic B16 melanoma mouse model. The obtained results demonstrated the great potential of LINFU for
designing MRI-guided protocols aimed at visualizing the release of drugs from liposomal carriers. This study
could bring to the development of a new therapeutic for personalized medicine.
Keywords: Liposomes, Ultrasound, Non-Focused Ultrasound, MRI, Image-Guided Drug-Release,
Theranostics.
1. INTRODUCTION
Liposomes are widely used in medicine as drug carriers because
they can significantly reduce systemic drug toxicity and improve
drug accumulation and bioavailability at the target site.12 Once
there, the liposomal shuttles must deliver their cargo to the dis-
eased cells, thereby enabling the drug to exert the desired ther-
apeutic effect. The release of the drug from the nanovesicle is
a crucial step that controls the overall success of the therapy.
An improvement of the stability of the liposomal formulation
associated with the optimization of the pharmacokinetics of the
nanomedicine (e.g., use of active targeting approaches) reduces
the potentially harmful systemic release of the drug, thereby
increasing the accumulation of the carrier at the target site. How-
ever, highly stable carriers may jeopardize the release of the drug
at the pathological site. For this reason, there is the demand of
more sophisticated release modes in which the drug is released
upon the occurrence of a proper stimulus. Triggering stimuli can
be grouped in endogenous (e.g., pH, enzymatic activity, redox
∗Author to whom correspondence should be addressed.
potential) or externally applied (e.g., heat, light, ultrasound).3
Typically, ultrasound (US) can stimulate the release of mate-
rial encapsulated in thermo-sensitive liposomes through the tem-
perature rise associated with the application of High-Intensity
Focused Ultrasound (HIFU).4–7 Though the use of HIFU has been
demonstrated successful, a mechanic release induced by non-
focused US might bring benefits as the reduction of potential
heat-associated side effects, and the extension of the US trig-
gered approach also to non thermosensitive carriers. The release
of material encapsulated in non-thermo sensitive liposomes using
low intensity non focused US has been first reported by Lin and
coworkers.89 There is a consensus on the view that the mechanic
release occurs through the formation of transient pores in the
liposomes bilayer, with a minor contribution from vesicle dis-
ruption, likely associated with inertial cavitation effects or intrin-
sic instability of the carrier.10–12 However, irrespectively from
the specific mechanism involved, several variables either related
to the acoustic radiation (e.g., intensity, duration, frequency) or
dependent on the liposome characteristics (e.g., bilayer compo-
sition, size) can affect the release. The interplay of such vari-
ables, combined to the intrinsic complexity of the US set up,
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makes the comparison among literature reports rather difficult.
The improvement of the therapeutic outcome using liposomal
drugs exposed to non-focused US has been already demonstrated
in vivo on experimental tumor models13–16 after the in vitro opti-
mization of the release efficiency.17
Recently, nanomedicine has received a strong impulse from
the emerging field of “theranosis,” 18 which aims at developing
innovative strategies to provide an imaging19 support to therapies,
including the design of probes for the in vivo visualization of
drug delivery and release.2021
Among the available imaging technologies, Magnetic Reso-
nance Imaging (MRI) is certainly well suited for theranostic pur-
poses in virtue of its excellent spatio-temporal resolution and low
invasiveness. Typically, MRI contrast generates from chemicals
able to affect the relaxation times (T1 and T2 of the water pro-
tons. Paramagnetic Gd(III) complexes (as T1 agents) and super-
paramagnetic iron oxide particles (SPIO, as T2*/T2 agents) are
the most clinically relevant classes of MRI contrast agents.22
Importantly, liposomes are excellent carriers for both types of
agents, thereby offering valuable options for designing theranos-
tic procedures.2324
When the task is the visualization of drug release from lipo-
somal carriers, the best approach is to encapsulate a hydrophilic
paramagnetic agent in the aqueous nanovesicle core.2627 In fact,
in this case, one may go with “MRI silenced” liposomes that
can be obtained either by reducing the exchange rate of water
molecules across the liposomal membrane or by a proper control
of the relaxation rate of the water molecules in the inner aqueous
cavity. Then, the release of both the drug and the agent, removes
the “quenching” effect, thereby allowing the visualization of the
release process through the detection of a contrast enhancement.
Other strategies can be also adopted. For instance, it has been
shown that liposomes coated with hydroxyapatite and entrapping
nanodots of SPIO in the inorganic shell can release their con-
tent upon application of high frequency, low intense, continuous
US.28 In that case, the release of the liposomes payload was
associated with changes in negative T2*/T2-based MRI contrast.
The primary motivation of this work was to demonstrate, for
the first time, the potential of MRI to produce a positive contrast
enhancement following the LINFU-induced release of a Gd(III)-
based agent from stealth liposomes. The data collected in vitro
were corroborated by an in vivo proof-of-concept that highlighted
the ability of MRI to successfully detect the release of the lipo-
some content upon the local application of LINFU to an experi-
mental murine tumor model.
2. MATERIALS AND METHODS
2.1. Chemicals
DPPC (1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine), DSPC
(1,2-Distearoyl-sn-Glycero-3-Phosphocholine), DPPG (1,2-Di-
palmitoyl-sn-Glycero-3-Phosphoglycerol), POPC (1-Palmitoyl,
2-Oleyl-sn-Glycero-3-Phosphocholine), and DSPE-PEG-2000
(1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N -[Methoxy
(Polyethylene Glycol)-2000], Ammonium salt) were purchased
from Avanti Polar Inc. (Alabaster, Al, USA). (PolyEthylene-
Oxy)25-(PolyButadiene)40 di-block copolymer was purchased
from Polymer Source (Quebec, Canada). Gadoteridol was kindly
provided by Bracco Imaging SpA (Colleretto Giacosa, TO,
Italy). The dimeric complex Gd-1 was synthesized according to
the procedure reported elsewhere.29
All the other chemicals were purchased from Sigma-Aldrich
(St. Louise, MO, USA).
The cell culture medium RPMI 1640, fetal bovine serum
(FBS), glutamine, penicillin-streptomycin mixture and EDTA
were purchased from Cambrex (East Rutherford, NJ, USA).
2.2. Nanovesicle Preparation
Nanovesicles were prepared according to the thin film hydra-
tion method.30 The total amount of membrane components for
each preparation was 20 mg/ml. Seven types of vesicles were
prepared:
(i) DPPC/DSPE-PEG2000 (95/5 molar ratio),
(ii) DSPC/DSPE-PEG2000 (95/5 molar ratio)
(iii) DPPC/DPPG (95/5 molar ratio),
(iv) DPPC/Chol/DSPE-PEG2000 (55/40/5 molar ratio),
(v) DSPC/Chol/DSPE-PEG2000 (55/40/5 molar ratio),
(vi) POPC/Chol/DSPE-PEG2000 (55/40/5 molar ratio), and
(vii) (PolyEthyleneOxy)22-(PolyButadiene)40 (polymersomes).
The thin lipid films were loaded with Gadoteridol (300 mM solu-
tion) or Gd-1 (200 mM solution). The mean hydrodynamic diam-
eter of the liposomes was determined by dynamic light scattering
(DLS) measurements carried out on a Malvern ZS Nanosizer
(Malvern Instrumentation, UK).
2.3. Release Measurements
The quantitative assessment of probe release after the exposure of
the liposomal suspension to US was performed in vitro at 0.5 T
on a fixed frequency relaxometer (Stelar, Mede (PV), Italy). The
percentage of Gadoteridol release was calculated using the fol-
lowing expression:47
Percentage of release%= R
US
1 −Rno−US1
RTriton1 −Rno−US1
·100 (1)
where RUS1 refers to the longitudinal relaxation rate of the liposo-
mal sample after insonation, Rno–US1 is the relaxation rate of the
same, non-insonated, sample (where all the Gd-based agent is
entrapped in the nanovesicles), and RTriton1 is the relaxation rate
of the liposomal suspension in which the encapsulated probe has
been fully released upon addition of 10% V/V of Triton-X100.
2.4. Animal Model
6 to 10-week-old female C57Bl6 mice (Charles River Labora-
tories, Calco, Italy) were subcutaneously inoculated in the left
foreleg with 0.2 ml of a suspension containing approximately
1 million of B16 murine melanoma cells. B16 cells were grown
in RPMI 1640 medium supplemented with 10 % of FBS, 2 mM
of glutamine, 100 U/ml of penicillin, and 100 g/ml of strep-
tomycin. B16 (murine melanoma) cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
Experiments were performed according to the national regula-
tions and were approved by the local bioethical.
2.5. MRI Measurements
T1-weighted MR images were acquired at 7.05 T on a
Bruker Avance 300 (Bruker BioSpin, Milano, Italy) spectrometer
equipped with a Micro 2.5 microimaging probe. The measure-
ment of the magnetic susceptibility of the liposomes suspension
allowed the determination of the total concentration of the param-
agnetic complex according to a previously reported procedure.31
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When the tumor reached a mean diameter of about 4 mm
(ca. 7 days after cell inoculation), 20 l of the DSPC/DSPE-
PEG-2000 liposomes suspension were directly inoculated in the
lesion.
A series of T1w images (Spin-Echo sequence, TE = 33 ms,
TR = 250 ms), were acquired before and after liposome injec-
tion, and then after the tumor exposure to pulsed LINFU. A total
number of 3 mice were examined.
MRI T1 contrast was calculated in the region of interest (ROI)
encompassing the whole tumor from the water signal intensity,
and expressed as percentage enhancement (SIenh%) according the
following formula:48
SI enh%= SIpost −SIpre
SIpre
·100
where SIpre and SIpost are the signal intensity (both normalized
with respect to an external reference), before and after the intra-
tumor injection of the liposomes suspension, respectively.
2.6. Ultrasound Apparatus
Pulsed LINFU was generated by the home-built system. The
circuit included by a piezoelectric flat transducer (Mastersonic
Company, Switzerland, diameter 4.5 cm), with a nominal res-
onance frequency of 28± 04 kHz and a maximum power of
50 W. US intensity was measured using a calorimetric method,
which is commonly used for the measurement of US intensity at
low frequency.323350 The US transducer was immersed in a ther-
mally insulated spherical flask made of latex and filled with water
at room temperature (without internal acoustic absorber). With
a duty cycle of 50% (tON = tOFF = 100 ms) and a cross-section
piezoelectric disk area of 15.9 cm2, an intensity ISAPA (SAPA=
Spatial Average Pulse Average) value of 58± 04 W/cm2 and
a spatial-average temporal-average intensity, ISATA, of 29 ±
03 W/cm2 were obtained . The acoustic pressure, calculated
from the US intensity was 0.21 MPa. On this basis, a Mechanical
Index of 1.25 was obtained. The used transducer was a system
approved for human use and it was connected to:
(i) a pilot circuit with variable resistance (TEMAT electronic,
distributed by C. Quaranta Srl, Chieri (TO), Italy),
(ii) an oscilloscope (Tektronix TDS1001B),
(iii) a multimeter (Fluke 87 V), and
(iv) an attenuated (100×) oscilloscope probe for the connection
to the circuit.
The multimeter was inserted in series into the power connec-
tion heads in the US transducer to monitor the current absorption
during the operation of the piezoelectric component. The oscil-
loscope was connected in parallel to the feeding circuit to find
the frequency and the amplitude of the tension signal.
Working at variable resistance, some variations in transducer
power current supply were observed, with a sensibility of ca.
0.1 A. The probe frequency was calibrated at 276± 05 kHz
because at this resonant frequency the maximum value of cur-
rent absorption at the transducer (67± 03 A) and the minimal
frequency variability was observed. The oscilloscope allowed the
monitoring of the stability of the emitted pulsed US wave dur-
ing the transducer calibration and during liposome insonation
experiments. The experimental setup consisted of the US appa-
ratus, a cylindrical container filled up with an isotonic buffer and
internally coated by a polyurethane acoustical foam panels with
pyramidal sections (angle sides of 40 to prevent standing wave
formation),34 and a 50 m thick acoustically transparent latex
spherical container for the sample to be insonated.
2.7. Histological Evaluation
All the experiments on mice were conducted in accordance with
the Ethical guidelines of the University of Torino.
After US applications, animals from both experimental groups
(US treated and controls) were sacrificed under anesthesia by
cervical dislocation. Tissue samples from tumor, liver and kidney
were immersed overnight in Carnoy’s fixative solution at 4 C
and then embedded in paraffin. De-waxed 5 m sections were
stained with hematoxylin-eosin (H&E) and examined under a
light microscope.
3. RESULTS
3.1. Comparison Between Continuous and
Pulsed US Exposure on Nanovesicles
with Different Formulations
Stealth liposomes based on DSPC (mean hydrodynamic size
110±5 nm) and DPPC (mean hydrodynamic size 100±4 nm),
both encapsulating ca. 300 mM of the clinically approved T1
MRI agent Gadoteridol (Chart 1), were exposed to a continuous
(i.e., without signal stop) LINFU application for a time ranging
from 60 to 300 seconds; each sample was insonated only once
and then replaced with a new one (Fig. 1). In the following, all
the bars in the graphics will show the standard error calculated
by the propagation method, unless otherwise specified.
Differently from literature reports,2021 the observed profiles do
not have the hyperbole/exponential-like trend, but the release ver-
sus time is allometric (logarithmic linear) Y =A∗Xb , as demon-
strated by the analysis reported in Table I.
The liposome formulations used in this experiments have a
well-defined gel-to-liquid transition temperature (TM , DPPC ≈
41 C; DSPC ≈ 53 C), values at which the liposome bilayer
become leaky and the entrapped material is released.49 There-
fore, it was crucial to check whether the observed release was or
not mediated by a temperature increase caused by the US appli-
cation. To this purpose, temperature was measured directly in
the liposome suspension during the US exposure. The tempera-
ture readout after the longest US exposure (5 minutes) indicated
a temperature rise of only 2 C. This result is a robust indica-
tion that the release of Gadoteridol from the liposomes was not
heat-mediated.
3.2. Kinetics of Gadoteridol Release Upon
LINFU Exposure (Continuous Mode)
The release kinetics of Gadoteridol from the two formulations
was also monitored after the application of the LINFU stimulus.
The objective of this study was to check whether the US-induced
release occurs during the US application only, or it lasts longer.
Figure 2 shows that the release of the paramagnetic agent stopped
just after the US stimulus was switched off. This observation is a
clear demonstration that the insonation did not give rise to a long-
term destabilization of the vesicles. Furthermore, it emphasizes
the high grade of control that can be exerted on the LINFU-
triggered release.
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Chart 1. Gadoteridol (top) and Gd-1 (bottom).
3.3. From Continuous to Duty Cycle (Pulsed) LINFU
The release of Gadoteridol was also investigated by using pulsed
acoustic waves. Furthermore, to assess whether the release was
affected by the liposomes formulation, samples differing in
the chemical composition of the vesicle bilayer (presence of
cholesterol, unsaturated alkyl chains, PEG coating, di-block-
copolymers36 were prepared. Pulsed LINFU exposure consisted
of the application of a train of periodic and short (from 10 ms
to 1 s) US waves interleaved by periods in which the transducer
was switched off. The ratio between ON and OFF periods defines
the duty cycle percentage (DC%) that represents the fraction of
time in which the transducer is switched on.
Fig. 1. Release percentage of Gadoteridol as a function of the LINFU expo-
sure in continuous mode, (without duty cycle application) for stealth liposome
formulations based on DSPC and DPPC. Reported values are the average
of a group of five experiments performed for each insonation time and lipo-
somes type; bars represent the standard error.
Table I. Statistical results of the percentage release of Gadoteri-
dol with US continuous insonation from DPPC and DSPC stealth
liposomes. The results indicate a logarithmic linear fit model (In
Y = A+b ∗ InX ) as allometric relation that in both cases can explain
over 97% of the data obtained and the correlation coefficient r indicates
a highly significant relationship between this two variables (insonation
time and release of the liposomal content). The P-value of the Anova
test (<0.05) indicates a statistically significant relationship. Pearson’s
Correlation Coefficient values, r, strongly correlate insonation time with
Gd rel.%.
Fit model ANOVA
Y = release % Correlation
LIPOSOME X = insonation time R2 value r F test P -value
DSPC-PEG Y = 146∗X069 0.97 0.99 296,37 0,0004
DPPC-PEG Y = 148∗X07 0.97 0.99 222,86 0,0007
A duty cycle of 50% was used in the first series of experi-
ments, whereas the total US exposure was fixed at 3 min (i.e.,
1.5 min USON and 1.5 min USOFF for each experiment).
Surprisingly, the release profiles are strongly affected by the
ton values and, especially, by the physico-chemical characteris-
tics of the vesicles.
3.4. Release as a Function of Duty Cycle
To assess the role of the duty cycle, the release of Gadoteridol
from DSPC/DSPE-PEG2000 liposomes and DPPC/DSPE-
PEG2000 liposomes was determined as function of DC%,
keeping fixed tON at the values in which the two formulations
displayed the maximum release with a duty cycle of 50% (i.e.,
250 ms and 100 ms, respectively). The total US exposure was
lowered to 1 minute to avoid the possible saturation of the release.
The results shown in Figure 3 indicate that the increase of
DC% facilitates the release for both the formulations, with a
larger dependence observed for DSPC-based liposomes.
3.5. Effect of Liposome Shape and Payload
of the Encapsulated Agent
Some specific applications of liposomes as MRI agents require
the preparation of non-spherical vesicles.40 Furthermore, it has
been demonstrated that the shape of nanoparticles can influ-
ence their extravascular accumulation.41 For these reasons, it was
deemed of interest to test whether the shape of the vesicles could
affect their sonosensitivity. Beside that, it is also noteworthy to
evaluate the possible role of the intraliposomal concentration of
the entrapped molecule as well as its molecular size.
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Fig. 2. Time dependence of the release of Gadoteridol from stealth DPPC-
(squares) and DSPC-(circles) based liposomes after a single LINFU applica-
tion (exposure time: 2 min (white), 3 min (grey), and 4 min (black)). During
the experiment liposomes were kept at 25 C.
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Fig. 3. Dependence of the release of Gadoteridol on the duty cycle upon pulsed LINFU exposure. tON values were kept fixed to 100 ms and 250 ms. Left:
DSPC/DSPE-PEG2000 liposomes, Right: DPPC/DSPE-PEG2000 liposomes. Total insonation time 1 min.
3.6. MR Imaging: In Vitro Validation
As first experiment, a phantom containing non stealth DPPC-
based and stealth DSPC-based liposomes (previously insonated
for different times with a pulsed acoustic waves) was subjected
to a MR scan using a conventional T1-weighted pulse sequence
(Fig. 4).
The brightening observed upon increasing the insonation time
reflects the enhancement in the longitudinal relaxation rate of
the water protons, which is consequent to the release of the
paramagnetic agent. Moreover, the longitudinal relaxation rate
(R1 was determined for each sample and the results, sub-
tracted by the diamagnetic contribution (0.4 s−1 are reported in
Figure 5.
The data were modeled with an exponential function, whose
rate constant is related to the sonosensitivity of the liposomes.
On this basis, the release of the DSPC-PEG formulation is ca.
three-fold faster than that of DPPC-DPPG, as already predictable
from the data reported in Figure 6. However, for insonation time
Fig. 4. MRI T1w image (7.05 T , room temperature) of a phantom consist-
ing of several liposomal samples previously insonated with pulsed LINFU for
the time indicated close to the sample. DSPC/DSPE-PEG2000 liposomes
(left) was insonated using a tON value of 250 ms, whereas for DPPC/DPPG
liposomes (right) was used a tON value of 100 ms (DC% = 50%). The con-
centration of Gadoteridol in the suspensions was 0.75 mM and 1.5 mM for
DSPC/PEG and DPPC/DPPG, respectively.
longer than 10 minutes, the relaxation rate measured for the two
formulations were almost equal and in agreement with a com-
plete release of Gadoteridol.
3.7. MR Imaging: In Vivo Proof-of-Concept
The potential of pulsed LINFU to trigger a MRI detectable
release of Gadoteridol from liposomes was also preliminary
tested in vivo on mice bearing a subcutaneous syngeneic B16
melanoma (average tumor volume: 100 mm3. This experi-
ment, propaedeutic t future in vivo applications, was primarily
designed to investigate the release behavior of liposomes in a sys-
tem containing biological interfaces that can significantly influ-
ence the liposome response to the US stimulus. To this purpose, a
very small volume (20 L) of DSPC/DSPE-PEG2000 liposomes
loaded with Gadoteridol was injected directly in the tumor mass.
Then, the animals (n = 3) were subjected to a LINFU exposure
directed on the tumor.
Before LINFU exposure, a calibration of the applied US was
performed. The variable resistance circuit was adjusted until
obtaining a maximum power current of 10± 06 A, necessary
to maintain a stable frequency of 276±05 kHz. Variable resis-
tance adjustment led to an increase of the acoustic intensity pro-
portional to the increase in the absorption of current monitored
using the multimeter connected to the base of the piezoelec-
tric component. An acoustic intensity value (ISATA of 82± 04
W/cm2 was measured. This figure was higher than the corre-
sponding value determined for the in vitro experiments (29±
03 W/cm2. This difference was mostly due to the different US
attenuation caused by tissue thickness and interface effects occur-
ring in vivo.
The animals were placed in a special animal bed that is used
for the acquisition of MR images and then immersed in water up
to the abdomen with an angle of approximately 45 to minimize
reflections and ultrasonic beam attenuation. The US transducer
was then positioned in water parallel to the mouse and directed
at the sonication point with a distance of about 1.5 cm.
Furthermore, a phono-absorbing crown sponge was positioned
around the tumor lesion to border the exposure. The animal bed
had a hemi-cylindrical section, with a side opening, which allows
the mouse to be positioned correctly for US exposure, and for the
subsequent MRI scan, thus avoiding a repositioning procedure.
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Fig. 5. The graphs show the results obtained on R1 p value; this results were obtained with a concentration normalization versus 1. Right panel: DSPC-PEG
bilayer liposomes. Left panel: DPPC-DPPG bilayer liposomes (the panel within the graph contains the magnification of data in the first 60 seconds of exposure).
A different x-axis scale was necessary as the membranes showed different release efficiency. The bars represent the standard deviation.
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Fig. 6. Release profiles of Gadoteridol as a function of tON values (DC%= 50%, total US exposure: 3 minutes) from different formulations of nanovesicles:
DSPC/DSPE-PEG2000 95/5 120 nm (squares), DPPC/DSPE-PEG2000 95/5 130 nm (circles), DPPC/DPPG 95/5 130 nm (rhombic), polymersomes 190 nm
(stars), DSPC/Chol/DSPE-PEG2000 55/40/5 140 nm (upper triangles), DPPC/Chol/DSPE-PEG2000 55/40/5 160 nm (lower triangles), POPC/Chol/DSPE-
PEG2000 55/40/5 160 nm (asterisks).
The LINFU application was carried out with a duty cycle of
50%, a tON value of 250 ms, and a total sonication time of 2 min-
utes. Immediately after the exposure, the animal bed was repo-
sitioned in the MRI scanner and post US images were acquired
(Fig. 7).
Table II. R1 pvalues statistical parameters. Exponential relationship
was demonstrated in both cases (R2 values).
Liposome Fit model R2
DSPC-PEG y = A∗ 1−exp−k ∗x y = release % 0.98
k = release rate
x = insonation time
Value Standard error
A= 222 0.09
k = 003 0.001
DPPC-DPPG y = A∗ 1−exp−k ∗x y = release % 0.91
k = release rate
x = insonation time
Value Standard error
A= 1.98 0.32
k = 0.009 0.003
The bright spot observed in the insonated area tumor clearly
indicate the effective release of the paramagnetic agent. Further-
more, as Gadoteridol is rapidly excreted by kidneys, a large T1
contrast was also detected in the bladder just after the LINFU
application.
Finally, classical histology exams were performed to check
possible cellular damages caused by LINFU exposure. No signs
of necrosis and disruption of vascular structures were detected,
at least by means of light microscopy examination, either in
tumor (Fig. 8) or in distant organs (kidneys and liver).
4. DISCUSSION
This work was mainly aimed at evaluating the potential of MRI to
visualize the release of material (e.g., drugs) from nanovesicular
carriers stimulated by low frequency non focused US. To achieve
this goal, the most straightforward approach was to fill the
nanocarrier with a T1 paramagnetic agent. In fact, when the relax-
ation time of the water protons of the aqueous core of the vesicle
is shorter than the average residence time of the water in the
core (T intra1 < t
intra, then the ability of the paramagnetic complex
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Fig. 7. Axial MR images (7.05 T) of one of the three mice examined bearing
a B16 melanoma (indicated by the green line). I and II: T2w images; III and IV:
T1w images. I and III: images acquired after liposome injection in the tumor.
II and IV: images acquires after local pulsed LINFU application (tON 100 ms,
DC% = 50%, total insonation time 3 minutes). The bright spot outside the
tumor (comprised in the red circle) observed in image IV corresponds to
the lower portion of the bladder and it arises from the renal excretion of
Gadoteridol.
to relax the bulk water protons is “quenched.” For this reason,
the quenching requires the entrapment of high amounts of the
paramagnetic probe (to reduce T intra1  in a vesicle with a low-
permeable membrane (to elongate tintra. When the relaxivity of
the entrapped agent is limited by water permeability35 of the
vesicle membrane, the release of the probe is accompanied by
a relaxation rate enhancement. Besides quantifying the release
efficiency in vitro, this phenomenon is the basic concept for the
MRI visualization of the release in vivo.
As first experiment the release of the clinically approved agent
Gadoteridol from conventional DSPC- or DPPC-based stealth
liposomes was investigated under the application of continuous
low frequency (28 kHz) non focused acoustic waves.
DPPC-based vesicles showed a slightly higher tendency to
release their content (ca. 10% difference after 5 min) than DSPC
liposomes. It has already been reported that the nature of the
phospholipids in the liposome bilayer plays an important role in
the sonosensitivity of the vesicle, though an accurate comparison
among the published data is not possible due to the differences
Fig. 8. Histological evaluation. Representative images of tumor tissue from
insonated (left) and control (right) mice (×200, hematoxylin-eosin).
in the used experimental setup. However, it is noteworthy that
the release of Gadoteridol was very high (> 80%) for both for-
mulations after 5 minutes of exposure (Fig. 1).
Another important finding is illustrated in Figure 2. In fact, the
observation that the release occurs only during the US exposure,
thereby not affecting the overall stability of the vesicles, allows a
high control of the release, and it indicates that the US-mediated
mechanism occurs on a very short time-scale without appreciable
long-term effects on the vesicle structure.
A relevant result of this study is the assessment of the effects
caused by the application of pulsed LINFU, in which a new set
of variables (e.g., the length of the pulse and the duty cycle),
potentially influencing the sonosensitivity of the vesicles, are
introduced in the experimental setup.
For instance, the release profile appeared strongly affected by
the tON values (Fig. 6), as well as by the chemical composition of
the bilayer. The results obtained can be summarized as follows:
(i) DSPC-based liposomes generally showed the highest release
at any tON values,
(ii) the incorporation of pegylated phospholipids (stealth lipo-
somes) favored the release,
(iii) polymeric nanovesicles like polymersomes showed the low-
est release, and
(iv) the incorporation of cholesterol (Fig. 6 right) caused a gen-
eral reduction of the release.
Contrarily to what reported in literature,17 we found that the
application of pulsed US promotes the release. As example, the
release from DSPC-based formulation increased from 50% (con-
tinuous LINFU) to 95% (tON 250 ms, DC% = 50%, 3 minutes
of sonication).
Unexpectedly, pulsed LINFU induced a differential release
even for liposomes differing for only 2 carbon atoms in their
principal phospholipid component, as clearly evident by com-
paring nanovesicles based on DSPC (C18 chains) and DPPC
(C16 chains). Using a short tON value of 10 ms (DC% =
50%, total exposure time 3 min), the release from DSPC-based
vesicles was more than 200% higher than DPPC-based liposomes
(Fig. 6). Similar, or even higher, differences in the release extent
were observed for other formulations like non-stealth liposomes,
polymer-based vesicles, and cholesterol-containing liposomes.
The reduced release observed for the non-stealth DPPC/DPPG
formulation agreed with data already reported in literature, where
it was accounted for in terms of a sort of “antenna effect” played
by the PEG coating that can favor the interaction between the
acoustic waves and the vesicles.15
On the other hand, the lower release efficiency observed for
cholesterol-containing liposomes and for polymersomes (which
are exclusively made of amphiphilic di-block copolymers), it is
likely the consequence of the higher stiffness of the result-
ing bilayers. Several publications correlated sonosensitivity with
vesicles formulation,37–39 but the different insonation setup, as
well as some controversial results, makes difficult to find a gen-
eral rationale.
Another important observation is the good release obtained
with POPC-based liposomes. In fact, this partially unsaturated
phospholipid has a low TM value (−2 C) that prevents a
temperature-mediated release at T > 0 C. Hence, this finding is
an additional support to the view that the release is not induced
by heating.
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Fig. 9. Release profiles of Gadoteridol from DPPC/DSPE-PEG2000 lipo-
somes upon pulsed LINFU application. Squares: liposomes encapsulating
300 mM of Gadoteridol. Circles: liposomes encapsulating 50 mM of Gado-
teridol. Stars: non-spherical liposomes prepared encapsulating 40 mM of
Gadoteridol and dialyzed against hyper-osmotic buffer to induce a change
in vesicle shape.39 The vesicles had hydrodynamic diameters comprise in
the 120–130 nm interval. Figure 5-clearly highlights the dependence of
the sonosensitivity of the liposomes on shape and concentration of the
entrapped material.
Taken together, these results not only indicate that the pulse-
rate of the US application strongly affects the release efficiency,
but also that the relationship between tON and the composition of
the vesicles can be positively exploited to envisage therapeutic
protocols in which US can induce a selective, triggered release
of a specific drug in spatial- and time-controlled way.
The release was also affected by the duty cycle of the pulsed
scheme, with a general enhancement of the release upon increas-
ing DC% (Fig. 3). Furthermore, the release observed for DSPC-
based liposomes was more sensitive to DC% than DPPC-based
vesicles, thereby outlining once again the great versatility of
using a pulsed scheme to control the release.
Other factors, like vesicle shape, and type and concentration
of the entrapped agent, were also evaluated. Figure 9 suggests
that both shape and intravesicular composition may contribute to
the release profile. Particularly interesting was the effect caused
by the change in the vesicles shape. In this case, the effective
concentration of Gadoteridol in the osmotically shrunken vesicles
is higher than the amount used in the hydration of the lipid film
(here 40 mM), due to the leakage of water during the shrinkage
of the vesicles. However, it has been estimated that the reduction
in the inner volume of the vesicles leads to a four-fold increase
in the concentration of the entrapped agent.42 This means that
if the liposomes were spherical, the release profile should lie
somewhere in the middle between the release observed for the
formulations entrapping 50 mM and 300 mM of Gadoteridol.
As this was not the case, the conclusion is that the shape of
the liposomal carrier is a relevant factor for the LINFU-triggered
release.
To assess the role of the size of the encapsulated agent, the
release of a paramagnetic agent bigger than Gadoteridol (the
dimeric Gd-1 complex reported in Chart 1)15 was investigated.
The release of Gd-1 from DSPC/DSPE-PEG2000 liposomes was
completely comparable with that one observed for Gadoteridol
either at tON 100 ms or at tON at 250 ms (data not shown),
thereby indicating that, at least for the agents here considered, the
size of the encapsulated chemical does not influence the release
properties.
Previous studies hypothesized that low frequency non-focused
ultrasounds can trigger the release from water-filled nanovesicles
primarily by two mechanisms: (i) transient destabilization on the
vesicle membrane, and (ii) vesicle disruption induced by inertial
cavitation (IC), with a predominance of the former.121416 How-
ever, other mechanisms, likely concomitant, could contribute to
explain the results obtained.
In this work, we found that LINFU application did not
affect hydrodynamic size and vesicles count (measured by DLS),
thereby suggesting that, differently from HIFU,3843 IC should
not play a relevant role. Moreover, the occurrence of massive
inertial cavitation effects can be also excluded by looking at the
histology results discussed previously, and it is also important
to outline that the inertial cavitation threshold is generally much
higher using short pulses, short total insonation time and low
duty-cycle values.51
Hence, the release mechanism might involve stable cavitation
(SC) effects. SC induces an oscillation of the vesicles that do
not reach the critical size beyond that IC takes place. The oscil-
lation may lead to a transient and instantaneous destabilization
of the membrane structure that results in the fast leakage of the
liposomal content.
However, the release model should take into account for other
experimental observations herein reported. First, the release is
strongly affected by the LINFU application mode: continuous or
pulsed. Importantly, in case of the latter mode, the investigated
liposome formulations (with the only exception of DSPC/DSPE-
PEG2000 liposom s) displayed a specific tON values (typically
in the range 100–300 ms) at which the release was maximal.
Therefore, this behavior is somehow correlated with the different
physical and mechanical properties of the vesicles (e.g., mass,
elasticity, compressibility, membrane compactness and so on).
The remarkable dependence of the release on tON and duty cycle
values could be related to the low-frequency component (Hz
scale) generated by the pulsed mode that modulates the carrier
acoustic wave (28 kHz). Moreover, the release model should also
justify the unexpected role played by the shape and the compo-
sition of the vesicles cavity (see Fig. 9).
Nevertheless, the development of a reliable physico-chemical
model to shed more light on the mechanism that governs the
release of liposomal content triggered by pulsed LINFU was
beyond the scope of this work, and it will be tackled in future
studies.
A first in vitro experiment to assess the MRI potential for
the visualization of release is reported in Figure 4. A good T1
contrast enhancement (brightening), dependent on the release
extent R1p, was observed (Fig. 4); release rate coefficients can
be obtained through the fitting of a R1p values as function of
insonation time, to quantify the mean release velocity (Fig. 5).
Fitting data show two different liposomes k-velocity release val-
ues: lowest k DPPC/PEG value indicates release rate lower than
the DSPC/PEG liposome.
The data confirmed the possibility to visualize the selec-
tive release from a mixture of liposomes having different
sonosensitivity trough the selection of an appropriate choice of
US exposure and tON values. As already discussed, DSPC-based
liposomes was much more prone to release their content upon
LINFU exposure.
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Fig. 10. Left: Histology (×200, hematoxylin-eosin) on a kidney of a mouse subjected to US exposure on the tumor. Right: control (i.e., non insonated mouse).
Fig. 11. Left: Histology (×200, hematoxylin-eosin) on a liver of a mouse subjected to US exposure on the tumor. Right: control (i.e., non insonated mouse).
On the basis of these promising results, we deemed of inter-
est to get an in vivo proof-of-concept, with the primary aim of
developing an insonation setup optimized for in vivo experiments.
Then, a small volume of a suspension containing DSPC-based
liposomes entrapping Gadoteridol was injected in a subcutaneous
syngeneic melanoma B16 tumor.
As the result of the local LINFU application, a very good T1
contrast enhancement44 (180± 26%) was detected in the lesion,
thus paving the way for future preclinical/clinical translations.
To check the bio-safety of the pulsed LINFU setup used for
the in vivo experiment, a standard histology assessment on the
explanted tumor, kidneys, and liver was carried out.
Tumor masses were composed by melanocytes with different
grades of nuclear and cytoplasmic anomalies. Neoplastic cells
were arranged in nets and trabeculae embedded in a stroma with
a high level of angiogenesis (Fig. 8). Ultrasound treatment did
not produce any additional alteration on tumor morphology. Scat-
tered tumor necrotic cells were also observed in the specimen not
exposed to US. Moreover, the anatomical integrity of the blood
vessels walls, independently of their caliber, was also preserved,
as no evidence of erythrocytes extravasation was detected. Fur-
thermore, there were not observed elements of damage in the
liver and kidney sections belonging from both groups of animals
(Figs. 10 and 11).
5. CONCLUSIONS
In this work, the potential of MRI as non-invasive imaging tool
for the in vivo visualization of LINFU-induced drug release
from nanovesicular carrier was successfully demonstrated for
the first time. The main potential advantage of the application of
pulsed non focused acoustic waves is the possibility of design-
ing new improved therapeutic schemes where different drugs,
loaded in proper nanocarriers, could be selectively released in
very controlled way by selecting proper values of tON, duty cycle,
and/or total insonation time. The use of this insonation scheme
allows the reduction of the exposure times, keeping high the
release efficiency, and avoiding cavitation damages. Additionally,
as it has been demonstrated that liposomes containing paramag-
netic complexes in their inner cavity also act as T2 agents,2245
the herein proposed system could report simultaneously on both
drug-delivery46 (via T2-based imaging) and drug-release (via T1-
based imaging). Work is currently on going in our laboratory
aimed at:
(i) translating the herein reported results to a preclinical stage
in which the paramagnetic nanocarrier (also loaded with a given
drug) is administered intravenously,
(ii) developing a theoretical model to accurately describe the
release mechanism in order to optimize the overall performance
of the theranostic protocol, and
(iii) to explore the use of higher, and more clinical translatable,
US frequencies (e.g., 1–3 MHz).
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